Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
What Gilead wants its remdesivir bottle to look like. Photo: U.S. Patent and Trademark Office
Gilead Sciences is still testing its potential coronavirus treatment, but here's a sign the company may be expecting good news: It has applied for a trademark for the drug's packaging.
Why it matters: "The reason you make this trademark is because you think you're going to get a product out there soon," said Josh Gerben, a trademark lawyer who first noticed Gilead's application. "This is part of your brand protection."
The big picture: Gilead's drug, remdesivir, is seen as a promising candidate to treat the novel coronavirus, but is still undergoing clinical trials and hasn't been proven to work.
- Gilead is slated to release new data on remdesivir data later this month, from randomized trials in China.
- Filing for a packaging trademark indicates the company is seriously thinking about this drug's branding and mass distribution.
What they're saying: A Gilead spokesperson says the trademark application "is par for the course" and "entirely consistent with our stated responsibility to plan for a potential regulatory authorization should remdesivir be proven safe and effective."
Gilead has already trademarked the same blue-and-gray bottle top and white labeling in other federally approved drugs.